¼¼°èÀÇ Àå¼ö ¹× Ç׳ëÈ­ ¿ä¹ý ½ÃÀå : ¿¹Ãø - ¿ä¹ý À¯Çüº°, ¿ëµµº°, ÃÖÁ¾ »ç¿ëÀÚº°, Áö¿ªº° ºÐ¼®(-2032³â)
Longevity and Anti-Senescence Therapy Market Forecasts to 2032 - Global Analysis By Therapy Type (Senolytics, Gene Therapy, Cell Therapy, Mitochondrial Therapy, Immunotherapy, and Other Therapy Types), Application, End User and By Geography
»óǰÄÚµå : 1798008
¸®¼­Ä¡»ç : Stratistics Market Research Consulting
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 200+ Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,150 £Ü 5,849,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,250 £Ü 7,399,000
PDF (2-5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 5ȸ±îÁö °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,350 £Ü 8,950,000
PDF & Excel (Site License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 5ȸ±îÁö °¡´ÉÇÕ´Ï´Ù. Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ¹× Excel ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,500 £Ü 10,571,000
PDF & Excel (Global Site License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 10ȸ±îÁö °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Stratistics MRC¿¡ µû¸£¸é ¼¼°èÀÇ Àå¼ö ¹× Ç׳ëÈ­ ¿ä¹ý ½ÃÀåÀº 2025³â¿¡ 370¾ï 5,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ°í, ¿¹Ãø ±â°£ Áß CAGR 8.1%·Î ¼ºÀåÇÒ Àü¸ÁÀ̸ç, 2032³â¿¡´Â 639¾ï 1,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.

Àå¼ö ¹× Ç׳ëÈ­ ¿ä¹ýÀ̶õ ³ëÈ­¿Í °ü·ÃµÈ »ý¹°ÇÐÀû °úÁ¤À» Ç¥ÀûÀ¸·Î ÇÔÀ¸·Î½á ¼ö¸í ¿¬Àå°ú ¿¬·É¿¡ µû¸¥ °Ç°­ »óÅ °³¼±À» ¸ñÀûÀ¸·Î ÇÑ ÀÏ·ÃÀÇ ÀÇ·á °³ÀÔÀ» ¸»ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Ä¡·á¹ýÀº ¿¬·É °ü·Ã ÁúȯÀÇ ¹ßº´À» ´ÊÃß°í, ¼¼Æ÷ ±â´ÉÀ» °­È­Çϸç, Àü¹ÝÀûÀΠȰ·ÂÀ» ÁõÁø½ÃŰ´Â µ¥ ÁßÁ¡À» µÓ´Ï´Ù. ¼¼Æ÷ Àå¾Ö¿Í ¿°Áõ°ú °°Àº ³ëÈ­ÀÇ ±Ùº»ÀûÀÎ ¸ÞÄ¿´ÏÁòÀ» ´Ù·ç´Â °ÍÀ¸·Î, ÀÌ·¯ÇÑ Ä¡·á¹ýÀº »ýȰÀÇ ÁúÀ» °³¼±ÇÏ°í °Ç°­ ¼ö¸íÀ» ¿¬ÀåÇÏ·Á°í ÇÏ´Â °ÍÀÔ´Ï´Ù.

¹Ì±¹ ½ÉÀåÇùȸÀÇ µ¥ÀÌÅÍ¿¡ µû¸£¸é 2020³â ¹Ì±¹¿¡¼­´Â Æò±Õ 40ÃÊ¿¡ 1¸íÀÌ ³úÁ¹ÁßÀ» ¹ßº´Çϰí 19¸í Áß 1¸íÀÌ »ç¸ÁÇÑ´Ù°í ÇÕ´Ï´Ù.

¾ÈƼ ¿¡ÀÌ¡ Á¦Ç°¿¡ ´ëÇÑ ¼ÒºñÀÚ ÀÇ½Ä Áõ°¡

¼¼°è »ç¶÷µéÀÇ °Ç°­ ÀǽÄÀÌ ³ô¾ÆÁö°í ³ªÀÌ¿Í °ü·ÃµÈ Áúº´°ú ´«¿¡ º¸ÀÌ´Â ³ëÈ­ÀÇ Â¡ÈÄ¿¡ ´ëÇÑ Á¤º¸°¡ ´Ã¾î³²¿¡ µû¶ó È¿°úÀûÀÎ Ä¡·á¹ý°ú Á¦Ç°¿¡ ´ëÇÑ ¼ö¿ä°¡ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. ¼Ò¼È ¹Ìµð¾î, ¿Â¶óÀÎ °Ç°­ Ç÷§Æû, ±¤¹üÀ§ÇÑ ¸¶ÄÉÆÃÀº ³ëÈ­ ¹æÁöÁ¦, º¸ÃæÁ¦, Àç»ý ¿ä¹ý°ú °°Àº Çõ½ÅÀûÀÎ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ÒºñÀÚÀÇ °è¸ùÀ» ÃßÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀǽÄÀº ¿¹¹æ ´ëÃ¥°ú ¶óÀÌÇÁ ½ºÅ¸ÀÏ °­È­ÀÇ Á¶±â µµÀÔÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. °Ô´Ù°¡, ¼ö¸í»Ó¸¸ ¾Æ´Ï¶ó °Ç°­ ¼ö¸íÀ» ¿¬ÀåÇÏ´Â °Í¿¡ ´ëÇÑ °ü½É Áõ°¡´Â Áõ°Å ±â¹Ý ¾ÈƼ ¿¡ÀÌ¡ Á¦Ç°¿¡ ¼ÒºñÀÚÀÇ ÅõÀÚ¸¦ ÃËÁøÇÏ°í ½ÃÀå ÀüüÀÇ ¼ºÀå°ú Çõ½ÅÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

ÃÖ÷´Ü Ä¡·á ºñ¿ë

À¯ÀüÀÚ Ä¡·á, Áٱ⼼Æ÷ Ä¡·á, ³ëÈ­ ¹æÁöÁ¦ µîÀÇ ÃÖ÷´Ü Ä¡·á¿¡´Â º¹ÀâÇÑ °³¹ß °úÁ¤, °í¾×ÀÇ ÀÓ»ó½ÃÇè, Ư¼ö ¼³ºñ°¡ ¿ä±¸µÇ´Â °æ¿ì°¡ ¸¹¾Æ °¡°Ýµµ ³ô¾ÆÁý´Ï´Ù. ÀÌ·¯ÇÑ ºñ¿ëÀº ƯÈ÷ ÁßÀú¼Òµæ Áö¿ª¿¡¼­ Àα¸ ´ëºÎºÐÀÇ Ä¡·á¿¡ Á¢±ÙÇÏ±â ¾î·Æ½À´Ï´Ù. ¶ÇÇÑ, º¸Çè Àû¿ë°ú »óȯ ¿É¼ÇÀÌ Á¦ÇѵǾî ÀÖ¾î ȯÀÚÀÇ °æÁ¦Àû ºÎ´ãÀ» ´õ¿í ¹æÇØÇϰí ÀÖ½À´Ï´Ù. ±× °á°ú ¾ÈƼ ¿¡ÀÌ¡ ¼Ö·ç¼Ç¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖÀ¸¸ç °æÁ¦Àû ºÎ´ãÀÇ Å©±â°¡ º¸±Þ°ú ½ÃÀå È®´ëÀÇ À庮ÀÌ µÇ°í ÀÖ½À´Ï´Ù.

¿ø°Ý ÀÇ·á ¹× µðÁöÅÐ °Ç°­ ¼Ö·ç¼Ç È®´ë

°¡»ó ÇコÄɾî Ç÷§Æû¿¡ ´ëÇÑ ¾×¼¼½º°¡ Áõ°¡ÇÔ¿¡ µû¶ó ȯÀÚ´Â Àü¹®ÀÇ¿Í »ó´ãÇϰí, °³Àο¡ ¸Â´Â ¾ÈƼ ¿¡ÀÌ¡ Ä¡·á °èȹ¿¡ ¾×¼¼½ºÇϸç, °Ç°­ ÁöÇ¥¸¦ ¿ø°ÝÀ¸·Î ¸ð´ÏÅ͸µ ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ µðÁöÅÐ º¯ÇõÀº ¿¹¹æ Äɾî, ¶óÀÌÇÁ ½ºÅ¸ÀÏ Áöµµ, ¸¸¼º Áúȯ °ü¸®ÀÇ Á¦°øÀ» °­È­ÇÏ´Â °ÍÀ̸ç, Àå¼ö¿¡ ÃÊÁ¡À» ¸ÂÃá Ä¡·áÀÇ Áß¿äÇÑ ¿ä¼ÒÀÔ´Ï´Ù. ¿þ¾î·¯ºí ±â±â ¹× ¸ð¹ÙÀÏ °Ç°­ ¾ÛÀº ³ëÈ­¿Í °ü·ÃµÈ ¹ÙÀÌ¿À¸¶Ä¿ÀÇ ½Ç½Ã°£ ÃßÀûÀ» °¡´ÉÇÏ°Ô ÇÏ¿© Àû±ØÀûÀÎ ÇコÄɾ ÃËÁøÇÕ´Ï´Ù. ¼ÒºñÀÚ°¡ ¿ø°Ý ÇコÄɾ ¼ö¶ôÇÏ´Â µ¿¾È, ¿ø°Ý ÀÇ·á´Â Àå¼ö Ä¡·áÀÇ ¹üÀ§¿Í ¿µÇâÀ» ¼¼°èÀûÀ¸·Î È®ÀåÇÏ´Â Æí¸®ÇÏ°í ºñ¿ë È¿À²ÀûÀΠä³Î·Î »ç¿ëµË´Ï´Ù.

ÁøºÎÈ­·Î À̾îÁö´Â ±Þ¼ÓÇÑ ±â¼ú Çõ½Å

ÇöÀçÀÇ Ä¡·á¹ý¿¡ ¸¹Àº ÅõÀÚ¸¦ Çϰí ÀÖ´Â ±â¾÷Àº º¸´Ù »õ·Ó°í È¿°úÀûÀÎ ¼Ö·ç¼ÇÀÌ µîÀåÇÔ¿¡ µû¶ó ÀÚ»ç Á¦Ç°ÀÌ ½Ã´ë¿¡ µÚóÁú ¼ö ÀÖ½À´Ï´Ù. ÀÌ ²÷ÀÓ¾ø´Â ÁøÈ­´Â Áö¼ÓÀûÀÎ ¿¬±¸°³¹ß ºñ¿ë, ±ÔÁ¦ ÀûÀÀ, Àü·«Àû ¹Îø¼ºÀ» ¿ä±¸Çϱ⠶§¹®¿¡ Áß¼Ò±â¾÷Àº ºÎ´ãÀÌ µÇ°í »ó¾÷È­°¡ Áö¿¬µÉ ¼ö ÀÖ½À´Ï´Ù. °Ô´Ù°¡, ÇコÄɾî Á¦°ø¾÷ü´Â Áï½Ã Ãß¿ùµÉ ¼ö ÀÖ´Â Ä¡·á¹ýÀÇ Ã¤ÅÃÀ» ÁÖÀúÇÏ°í ½ÃÀå ħÅõ¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ½À´Ï´Ù. °á°úÀûÀ¸·Î Çõ½ÅÀÇ ±Þ¼ÓÇÑ ¼Óµµ´Â Èï¹Ì·Î¿î ¹Ý¸é ºÒÈ®½Ç¼ºÀ» °¡Á®¿À°í °æÀï ¾Ð·ÂÀ» °­È­ÇÏ°í ¾ÈÁ¤ÀûÀÎ ½ÃÀå ¼ºÀåÀ» ¹æÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

COVID-19ÀÇ ¿µÇâ :

COVID-19 ÆÒµ¥¹ÍÀº ´çÃÊ ÀÓ»ó½ÃÇèÀÌ ¿¬±âµÇ¾î °ø±Þ¸ÁÀÌ È¥¶õ¿¡ Á÷¸éÇ߱⠶§¹®¿¡ Àå¼ö ¹× Ç׳ëÈ­ ¿ä¹ý ½ÃÀåÀÇ ¼ºÀåÀ» µÐÈ­½ÃÄ×½À´Ï´Ù. ÇコÄɾîÀÇ ¿ì¼± ¼øÀ§´Â ´çºÐ°£ À§±â °ü¸®·Î ¿Å°ÜÁ³°í, ³ëÈ­¿Í °ü·ÃµÈ Ä¡·á°¡ ¿Ï¸¸ÇØÁ³½À´Ï´Ù. ÀÌ·¯ÇÑ ÁÂÀý¿¡µµ ºÒ±¸Çϰí, ÆÒµ¥¹ÍÀº °Ç°­ ¼ö¸íÀ» ¿¬ÀåÇÏ°í ³ëÈ­ °ü·Ã À§Çè¿¡ ´ëóÇÒ Çʿ伺À» °­Á¶Çϰí, ÀÌ ºÐ¾ß¿¡ ´ëÇÑ »õ·Î¿î °ü½É°ú ÀÚ±Ý Á¦°øÀ» ºÒ·¯ÀÏÀ¸Ä×½À´Ï´Ù. »óȲÀÌ Á¤»óÈ­µÊ¿¡ µû¶ó Àç»ý ÀÇ·á ¹× ¿¹¹æ ÀÇ·á¿¡ ´ëÇÑ ³ë·ÂÀÌ ´õ¿í Áß¿äÇØÁö°í ½ÃÀåÀÌ È¸º¹µÇ±â ½ÃÀÛÇß½À´Ï´Ù.

¿¹Ãø ±â°£ µ¿¾È ³ëÀμº ¾à¹° ¿ä¹ý ºÐ¾ß°¡ ÃÖ´ë°¡ µÉ Àü¸Á

³ëÈ­ ¹× ¸¸¼º ÁúȯÀ¸·Î À̾îÁö´Â À¯ÇØÇÑ ³ëÈ­ ¼¼Æ÷¸¦ Á¦°ÅÇÒ ¼ö Àֱ⠶§¹®¿¡ ¿¹Ãø ±â°£ µ¿¾È ³ëÀÎ ¿ëÇØ ¾à¹° Ä¡·á ºÐ¾ß°¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ³ëÈ­¿Í °ü·ÃµÈ °Ç°­ ¹®Á¦ÀÇ °³¹ß, ¾ÈƼ ¿¡ÀÌ¡ Ä¡·á¿¡ ´ëÇÑ °ü½É Áõ°¡, AI¸¦ Ȱ¿ëÇÑ ¾à¹° °³¹ßÀÇ ÁøÀüÀÌ ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ÀúºÐÀÚ ³ëÈ­ Ä¡·áÁ¦¿Í ½Ä¹° À¯·¡ È­ÇÕ¹°°ú °°Àº Çõ½ÅÀûÀÎ ±â¼úÀÌ Àα⸦ ²ø°í ÀÖ½À´Ï´Ù. ½ÉÇ÷°ü°è ÁúȯÀ̳ª Ä¡¸Å µîÀÇ ÁúȯÀ» ´ë»óÀ¸·Î ÇÑ È°¹ßÇÑ ÀÓ»ó½ÃÇèÀ» ÅëÇØ »ý¸í°øÇÐ ±â¾÷ ¹× Á¦¾à±â¾÷À¸·ÎºÎÅÍÀÇ ÀÚ±Ý ¿øÁ¶ Áõ°¡¿¡ Èû¾²°í ÀÖÀ¸¸ç, Å« Áøº¸°¡ °¡Á®¿À°í ÀÖ½À´Ï´Ù.

¿¹Ãø ±â°£ µ¿¾È CAGRÀÌ °¡Àå ³ôÀ» °ÍÀ¸·Î ¿¹»óµÇ´Â °ÍÀº º´¿ø ¹× Áø·á¼Ò ºÐ¾ßÀÔ´Ï´Ù.

¿¹Ãø ±â°£ Áß º´¿ø ¹× Áø·á¼Ò ºÐ¾ß´Â ¸¸¼ºÁúȯ ȯÀÚ Áõ°¡, Àα¸µ¿ÅÂÀÇ °í·ÉÈ­, ¿¹¹æÀÇ·á·ÎÀÇ ½ÃÇÁÆ®¿¡ °ßÀÎµÇ¾î °¡Àå ³ôÀº ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ³ëÈ­ ¹æÁöÁ¦, Áٱ⠼¼Æ÷ Ä¡·á, À¯ÀüÀÚ °³ÀÔ µî ÃÖ÷´Ü ±â¼úÀÌ Ä¡·á Àü·«À» À籸¼ºÇϰí ÀÖ½À´Ï´Ù. AI¸¦ Ȱ¿ëÇÑ ÀǾàǰ °³¹ß°ú ¸ÂÃãÇü °í·ÉÈ­ ´ëÃ¥ µîÀÇ µ¿Çâµµ ±â¼¼¸¦ ´Ã¸®°í ÀÖ½À´Ï´Ù. ÁÖ¸ñÇÒ¸¸ÇÑ ÁøÀüÀ¸·Î´Â ½ÉÀåÁúȯ ¹× ³úÁúȯ¿¡ ´ëÇÑ ÀÓ»ó½ÃÇèÀ» µé ¼ö ÀÖÀ¸¸ç, ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö¿¡ ´ëÇÑ ÀÚ±Ý Á¦°ø Áõ°¡¿Í ÇコÄɾî ÁÖµµÀÇ Çõ½ÅÀ» µÞ¹ÞħÇÏ´Â ±ÔÁ¦ÀÇ Á¤ºñ°¡ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù.

ÃÖ´ë Á¡À¯À²À» Â÷ÁöÇÏ´Â Áö¿ª :

¿¹Ãø ±â°£ µ¿¾È ¾Æ½Ã¾ÆÅÂÆò¾çÀº °í·ÉÈ­, ¸¸¼º ÁúȯÀÇ ±ÞÁõ, Àû±ØÀûÀÎ ÇコÄɾ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ÃÖ´ë ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ³ëÈ­ Ä¡·á, À¯ÀüÀÚ ÆíÁý, Áٱ⠼¼Æ÷ Ä¡·á, ¹ÌÅäÄܵ帮¾Æ º¹±¸ µîÀÇ Ã·´Ü ±â¼úÀÌ Àα⸦ ²ø°í ÀÖ½À´Ï´Ù. AI¸¦ Ȱ¿ëÇÑ ÀǾàǰ °³¹ß, ¸ÂÃãÇü ³ëÈ­ Ä¡·á, Àç»ý ¾îÇÁ·ÎÄ¡ µîÀÇ µ¿ÇâÀÌ ´ëµÎÇϰí ÀÖ½À´Ï´Ù. ÁÖ¿ä Áøº¸·Î´Â ½ÉÀ庴 ¹× ³úÁúȯ¿¡ ´ëÇÑ Àӻ󿬱¸, »ý¸í°øÇп¡ ´ëÇÑ ÀÚ±Ý Á¦°ø Áõ°¡, °Ç°­ÇÑ ³ëÈ­ Çõ½ÅÀ» ÃËÁøÇÏ´Â Á¤ºÎÀÇ È£ÀÇÀûÀÎ ³ë·Â µîÀÌ ÀÖ½À´Ï´Ù.

CAGRÀÌ °¡Àå ³ôÀº Áö¿ª :

¿¹Ãø ±â°£ µ¿¾È ºÏ¹Ì´Â °í·ÉÈ­, ¸¸¼º °Ç°­ ¹®Á¦ Áõ°¡, ¿¹¹æ ÀÇÇп¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ °¡Àå ³ôÀº CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ³ëÈ­ Ä¡·á, À¯ÀüÀÚ ÆíÁý, Áٱ⠼¼Æ÷ ¿ëµµ, ¹ÌÅäÄܵ帮¾Æ Ä¡·á µîÀÇ ÃÖ÷´Ü ±â¼úÀÌ ÃÖÀü¼±¿¡ ÀÖ½À´Ï´Ù. ÁÖ¸ñÇÒ¸¸ÇÑ µ¿ÇâÀ¸·Î´Â AI¸¦ Ȱ¿ëÇÑ ÀǾàǰ °³¹ß, Ä¿½ºÅ͸¶ÀÌÁîµÈ ³ëÈ­ °³ÀÔ, Àç»ý ¼Ö·ç¼Ç µîÀ» µé ¼ö ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö¿¡ ´ëÇÑ ÀÚ±ÝÀÇ È®´ë, ³úÁúȯ°ú ½ÉÀåÁúȯÀ» ´ë»óÀ¸·Î ÇÑ Àӻ󿬱¸, Çõ½ÅÀ» ÃßÁøÇÏ´Â Çмú±â°ü ¹× Á¦¾à±â¾÷ÀÇ °­·ÂÇÑ ÆÄÆ®³Ê½Ê µî Å« ÁøÀüÀ» º¼ ¼ö ÀÖ½À´Ï´Ù.

¹«·á ÁÖ¹®À» ¹Þ¾Æ¼­ ¸¸µå´Â ¼­ºñ½º :

ÀÌ º¸°í¼­¸¦ ±¸µ¶ÇÏ´Â °í°´Àº ´ÙÀ½ ¹«·á ¸ÂÃã¼³Á¤ ¿É¼Ç Áß Çϳª¸¦ »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ¼­¹®

Á¦3Àå ½ÃÀå µ¿Ç⠺м®

Á¦4Àå Porter's Five Forces ºÐ¼®

Á¦5Àå ¼¼°èÀÇ Àå¼ö ¹× Ç׳ëÈ­ ¿ä¹ý ½ÃÀå : ¿ä¹ý À¯Çüº°

Á¦6Àå ¼¼°èÀÇ Àå¼ö ¹× Ç׳ëÈ­ ¿ä¹ý ½ÃÀå : ¿ëµµº°

Á¦7Àå ¼¼°èÀÇ Àå¼ö ¹× Ç׳ëÈ­ ¿ä¹ý ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

Á¦8Àå ¼¼°èÀÇ Àå¼ö ¹× Ç׳ëÈ­ ¿ä¹ý ½ÃÀå : Áö¿ªº°

Á¦9Àå ÁÖ¿ä ¹ßÀü

Á¦10Àå ±â¾÷ ÇÁ·ÎÆÄÀϸµ

AJY
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

According to Stratistics MRC, the Global Longevity and Anti-Senescence Therapy Market is accounted for $37.05 billion in 2025 and is expected to reach $63.91 billion by 2032 growing at a CAGR of 8.1% during the forecast period. Longevity and anti-senescence therapy refers to a range of medical interventions aimed at extending lifespan and improving health during aging by targeting the biological processes associated with senescence. These therapies focus on delaying the onset of age-related diseases, enhancing cellular function, and promoting overall vitality. By addressing the underlying mechanisms of aging, such as cellular damage and inflammation, these therapies seek to improve quality of life and increase the healthy years of life.

According to the data of American Heart Association, in 2020, average person in the U.S. has a stroke every 40 seconds, accounting for one out of every 19 deaths.

Market Dynamics:

Driver:

Increased consumer awareness of anti-aging products

As global populations become more health-conscious and informed about age-related diseases and visible signs of aging, demand for effective therapies and products has surged. Social media, online health platforms, and widespread marketing have further educated consumers about innovative solutions such as senolytics, supplements, and regenerative therapies. This awareness encourages early adoption of preventive measures and lifestyle enhancements. Moreover, the growing interest in extending healthspan rather than just lifespan is fueling consumer investment in evidence-based anti-aging products, driving growth and innovation across the market.

Restraint:

High costs of advanced therapies

Cutting-edge treatments such as gene therapy, stem cell therapy, and senolytic drugs often involve complex development processes, expensive clinical trials, and specialized equipment, leading to elevated pricing. These costs make such therapies inaccessible to a large portion of the population, particularly in low- and middle-income regions. Additionally, limited insurance coverage and reimbursement options further hinder patient affordability. As a result, despite growing interest in anti-aging solutions, the high financial burden remains a barrier to widespread adoption and market expansion.

Opportunity:

Expansion of telemedicine and digital health solutions

With increasing accessibility to virtual healthcare platforms, patients can now consult specialists, access personalized anti-aging treatment plans, and monitor health metrics remotely. This digital transformation enhances the delivery of preventive care, lifestyle coaching, and chronic disease management-key components of longevity-focused therapies. Wearable devices and mobile health apps enable real-time tracking of biomarkers related to aging, encouraging proactive health management. As consumers embrace remote healthcare, telemedicine serves as a convenient, cost-effective channel for expanding the reach and impact of longevity treatments globally.

Threat:

Rapid technological changes leading to obsolescence

Companies investing heavily in current therapies may find their products outdated as newer, more effective solutions emerge. This constant evolution demands continuous R&D spending, regulatory adaptation, and strategic agility, which can strain smaller firms and delay commercialization. Moreover, healthcare providers may hesitate to adopt therapies that could soon be surpassed, impacting market penetration. Consequently, while the rapid pace of innovation is exciting, it also brings uncertainty and intensifies competitive pressure, potentially disrupting stable market growth.

Covid-19 Impact:

The COVID-19 pandemic initially slowed the growth of the longevity and anti-senescence therapy market, as clinical trials were postponed and supply chains faced disruptions. Healthcare priorities shifted toward managing the immediate crisis, sidelining age-related treatments. Despite this setback, the pandemic underscored the need to enhance healthspan and address aging-related risks, sparking renewed attention and funding in the sector. As conditions normalized, the market began to rebound, with a stronger focus on regenerative and preventive healthcare approaches.

The senolytic drug therapy segment is expected to be the largest during the forecast period

The senolytic drug therapy segment is expected to account for the largest market share during the forecast period, driven by its potential to remove harmful senescent cells linked to aging and chronic illnesses. Increasing age-related health issues, rising interest in anti-aging treatments, and progress in AI-powered drug development are propelling growth. Innovations like small molecule senolytics and plant-based compounds are gaining traction. Significant advancements are being made through active clinical trials targeting diseases such as cardiovascular conditions and dementia, bolstered by increasing financial backing from biotechnology and pharmaceutical companies.

The hospitals & clinics segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the hospitals & clinics segment is predicted to witness the highest growth rate, driven by growing cases of chronic illness, aging demographics, and a shift toward preventive medicine. Cutting-edge technologies such as senolytics, stem cell therapy, and genetic interventions are reshaping treatment strategies. Trends like AI-driven drug development and customized aging solutions are gaining momentum. Noteworthy progress includes trials for heart and brain disorders, with rising biotech funding and supportive regulations enhancing healthcare-led innovation.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, fuelled by an aging population, a surge in chronic illnesses, and increased interest in proactive health management. Advanced technologies such as senolytics, gene editing, stem cell therapy, and mitochondrial restoration are gaining traction. Trends like AI-driven drug development, tailored aging treatments, and regenerative approaches are emerging. Major advancements include clinical research on heart and brain diseases, rising biotech funding, and favourable government initiatives promoting healthy aging innovations.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, propelled by an aging population, increasing chronic health issues, and heightened interest in preventive medicine. Cutting-edge technologies like senolytics, gene editing, stem cell applications, and mitochondrial therapies are at the forefront. Notable trends include AI-enabled drug development, customized aging interventions, and regenerative solutions. Significant progress includes expanded biotech funding, clinical studies targeting brain and heart diseases, and strong partnerships between academic institutions and pharmaceutical companies driving innovation.

Key players in the market

Some of the key players in Longevity and Anti-Senescence Therapy Market include Calico Life Sciences, Unity Biotechnology, Juvenescence Ltd., BioAge Labs, Sierra Sciences, Oisin Biotechnologies, Bristol-Myers Squibb, Merck & Co., Inc., AgeX Therapeutics, Inc., AbbVie Inc., Altos Labs Inc., Bayer AG, CohBar, Life Biosciences, Inc., and Insilico Medicine.

Key Developments:

In July 2025, Bayer signed a development and distribution agreement with French pheromones expert company M2i Group for the exclusive distribution of pheromone gels for the Asia-Pacific as well as the Latin America region and the United States building on its successful collaboration and related product launches in Europe and Africa.

In June 2025, BioAge Labs, Inc. announced advances in its apelin receptor (APJ) agonist programs that strengthen the Company's pipeline of approaches for obesity and other indications. BioAge has entered into an option agreement with JiKang Therapeutics ("JiKang") to potentially in-license a novel APJ agonist nanobody. BioAge has also filed a provisional patent application covering internally developed, novel small molecule APJ agonists.

In January 2022, Altos Labs(TM) (Altos(TM)) launched as a new biotechnology company dedicated to unraveling the deep biology of cellular rejuvenation programming. Altos' mission is to restore cell health and resilience to reverse disease, injury, and the disabilities that can occur throughout life. The company launches with a community of leading scientists, clinicians, and leaders from both academia and industry working together towards this common mission.

Therapy Types Covered:

Applications Covered:

End Users Covered:

Regions Covered:

What our report offers:

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Table of Contents

1 Executive Summary

2 Preface

3 Market Trend Analysis

4 Porters Five Force Analysis

5 Global Longevity and Anti-Senescence Therapy Market, By Therapy Type

6 Global Longevity and Anti-Senescence Therapy Market, By Application

7 Global Longevity and Anti-Senescence Therapy Market, By End Users

8 Global Longevity and Anti-Senescence Therapy Market, By Geography

9 Key Developments

10 Company Profiling

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â